Teva Pharmaceuticals Recalls Octreotide Acetate Due to Sterility Concerns at Contract Manufacturer Pharmathen
Teva Pharmaceuticals USA, Inc. has initiated a Class II recall of Octreotide Acetate for Injectable Suspension, impacting 2,200 kits nationwide. This action stems from FDA inspection findings at contract manufacturer Pharmathen International S.A. in Greece, revealing critical quality system deficiencies affecting sterility assurance. Procurement and supply chain leaders must assess immediate supply risks and diversify sourcing strategies.
FDA Inspection Uncovers Sterility Deficiencies at Pharmathen, Triggering Teva's Octreotide Acetate Recall
Teva Pharmaceuticals USA, Inc. has initiated a voluntary Class II recall, designated D-0519-2026, for its Octreotide Acetate for Injectable Suspension. This critical action, initiated on April 24, 2026, directly results from significant quality system deficiencies identified by the U.S. Food and Drug Administration (FDA) during a routine inspection at Teva's contract manufacturer, Pharmathen International S.A., located in Rodopi, Greece. The core issue is a "Lack of Assurance of Sterility" for the injectable product, a fundamental requirement for patient safety in parenteral medications. For procurement directors and regulatory affairs heads, this signifies a severe breakdown in Good Manufacturing Practices (GMP) at a key supplier, necessitating immediate review of all products sourced from Pharmathen. The FDA's findings underscore the agency's unwavering focus on sterile manufacturing processes, and any identified lapse can lead to substantial commercial and reputational damage, as evidenced by this nationwide recall affecting a vital therapeutic agent.
Pharmathen International S.A.: Contract Manufacturing Risks and Sterility Assurance Gaps for Injectables
Pharmathen International S.A., based in Greece, serves as the manufacturer for Teva's Octreotide Acetate for Injectable Suspension. The FDA's identification of quality system deficiencies at this facility directly implicates the integrity of their manufacturing processes for sterile products. For supply chain VPs, this event highlights the inherent risks associated with outsourcing critical manufacturing steps, particularly for sterile injectables where even minor deviations can have severe consequences. The recall specifically impacts Octreotide Acetate, a human prescription drug administered via intramuscular route, emphasizing the paramount importance of sterility assurance. Companies engaging with contract manufacturing organizations (CMOs) must implement rigorous oversight mechanisms, including regular audits and robust quality agreements, to ensure that CMOs adhere to global regulatory standards. Failure to do so, as demonstrated by this event, can lead to costly recalls, market withdrawals, and significant supply disruptions, directly impacting patient access and business continuity for downstream partners like Teva Pharmaceuticals.
Teva Pharmaceuticals' Nationwide Octreotide Acetate Recall: Supply Chain Disruption and Patient Impact
Teva Pharmaceuticals USA, Inc. is recalling 2,200 kits of Octreotide Acetate for Injectable Suspension, 30 mg, specifically Lot: 45011002 with an expiration date of March 31, 2027. This Class II recall, initiated voluntarily by Teva but prompted by FDA findings, affects product distributed nationwide in the USA. The specific product NDCs involved include Kit Carton: 0480-9262-08, Vial Label: 0480-9260-01, and Diluent Label: 0480-9263-21. For business development executives and procurement teams, this recall represents an immediate supply chain disruption for Octreotide Acetate, a drug used for specific medical conditions. The "ongoing" status of the recall indicates continued efforts to retrieve affected product from the market. Companies relying on Teva for this specific formulation must immediately assess their inventory, identify potential shortages, and communicate proactively with healthcare providers and patients to manage expectations and ensure continuity of care. The financial implications extend beyond direct recall costs, encompassing potential lost sales, inventory write-offs, and the significant effort required for market remediation.
Strategic Sourcing for Octreotide Acetate: Mitigating Supply Chain Vulnerabilities Post-Recall
In light of Teva's Octreotide Acetate recall, procurement directors must urgently re-evaluate their sourcing strategies for critical injectable medications. While specific alternative suppliers for Octreotide Acetate are not detailed in the available intelligence, the prudent course of action involves identifying and qualifying multiple manufacturers to prevent single-point-of-failure risks. This includes exploring suppliers in diverse geographical regions to enhance supply chain resilience against localized regulatory or operational issues. The qualification timeline for new sterile injectable manufacturers can be extensive, often spanning 12-24 months, encompassing facility audits, process validation, and regulatory approvals. Therefore, proactive engagement with potential alternative suppliers is crucial. Business development executives should also consider strategic partnerships or licensing agreements to secure long-term supply, ensuring that any new supplier demonstrates a robust quality management system and a strong track record of FDA compliance, thereby safeguarding against future sterility assurance deficiencies.
Escalating FDA Scrutiny: A Trend of Sterility Assurance Failures Across Pharmaceutical Manufacturing
The FDA's findings at Pharmathen International S.A. and the subsequent recall of Teva's Octreotide Acetate are not isolated incidents but reflect a broader trend of heightened regulatory scrutiny on sterility assurance within the pharmaceutical industry. Recent parallel events underscore this focus: Essential Wellness Pharma faced a Class II recall for its Progesterone Injection in June 2026 due to sterility assurance failures, and Spectra Medical Devices initiated a Class II recall for Lidocaine HCl Injection in the same month for similar deficiencies. For regulatory affairs heads, these events signal that the FDA is actively inspecting and enforcing stringent sterility standards across various product types and manufacturers. Companies must proactively review and strengthen their own quality systems, particularly in aseptic processing and environmental monitoring, to avoid similar enforcement actions. The cumulative impact of such recalls across the industry can erode public trust and increase regulatory burdens, making robust compliance a competitive differentiator and a fundamental requirement for market access.
Remediation Pathways and Future Regulatory Action for Pharmathen and Teva's Octreotide Acetate Supply
The "ongoing" status of Teva's Class II recall for Octreotide Acetate indicates that the firm is actively managing the market withdrawal. For Pharmathen International S.A., the contract manufacturer, the identified quality system deficiencies will necessitate a comprehensive remediation plan to address the FDA's concerns. This typically involves a detailed root cause analysis, implementation of corrective and preventive actions (CAPAs), and potential re-inspection by the FDA. Should Pharmathen fail to adequately address these deficiencies, further regulatory actions, including an FDA Warning Letter or even an Import Alert for products manufactured at their Greek facility, are highly probable. For Teva, this event underscores the critical need for enhanced vendor qualification and continuous monitoring of CMOs. Supply chain VPs must prepare for potential long-term disruptions to Octreotide Acetate supply if Pharmathen's remediation efforts are protracted or unsuccessful, necessitating a rapid pivot to alternative manufacturing solutions to maintain market presence and patient access.